Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2025

Pharma News, 2025

FDA Fast Tracks Investigational Nonopioid Treatment for Acute Pain
FDA Fast Tracks Investigational Nonopioid Treatment for Acute Pain
The Food and Drug Administration (FDA) has granted Fast Track designation to LTG-001 (Latigo Biotherapeutics, Inc.) for the treatment of acute pain.
Combination of approved drugs offers new strategies for acute myeloid leukemia
Combination of approved drugs offers new strategies for acute myeloid leukemia
The combined use of two well-known active substances can fight leukemic cells and limit their spread. This is the result of a study conducted by the Karl Landsteiner University of Health Sciences (...
Allegro reports positive safety data for its injectable osteoarthritis treatment in three preclinical studies
Allegro reports positive safety data for its injectable osteoarthritis treatment in three preclinical studies
Liege, Belgium – 4 March 2025. Allegro NV, a biomedical company developing a transformative nanotechnology-based treatment for degenerative joint disease, announced today that hydrocelin (ALG-00...
AbbVie enters obesity space with $2.3bn Gubra deal
AbbVie enters obesity space with $2.3bn Gubra deal
GlobalData estimates that the obesity market will be worth over $173.5bn in 2031.
Magnet Biomedicine and Lilly link for molecular glue therapeutics
Magnet Biomedicine and Lilly link for molecular glue therapeutics
Magnet Biomedicine has entered a partnership and licence agreement with Eli Lilly to discover, develop and commercialise oncology molecular glue therapeutics.
Novartis hands over $55M upfront to license preclinical hives prospect from Japan's Kyorin
Novartis hands over $55M upfront to license preclinical hives prospect from Japan's Kyorin
Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a licensing pact with Japanese biotech Kyorin that could be worth hundreds of milli...
Avenacy intros generic Zometa
Avenacy intros generic Zometa
Zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy and for the treatment of multiple myeloma and bone metastases of solid tumors, in conjunction with standard anti...
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Jasper Therapeutics, Inc., a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic s...
FDA accepts Alvotech, Teva's BLA for proposed Eylea biosimilar
FDA accepts Alvotech, Teva's BLA for proposed Eylea biosimilar
Eylea is a biologic used to treat eye disorders, including diseases which can lead to vision loss or blindness.
FDA gives Sanofi-Aventis green light for Novolog biosimilar
FDA gives Sanofi-Aventis green light for Novolog biosimilar
Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA.
Mission Nixes Preclinical Studies, Falls Back on Clinical Candidates
Mission Nixes Preclinical Studies, Falls Back on Clinical Candidates
Mission Therapeutics is down to its clinical assets MTX652 and MTX325, which work by disabling a key enzyme that interferes with the cell’s normal process of removing faulty or dysfunctional mitocho...
CHMP recommends AbbVie’s Rinvoq be approved for adult GCA
CHMP recommends AbbVie’s Rinvoq be approved for adult GCA
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie’s upadacitinib (Rinvoq) to treat adults with giant cell...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand